Company news

Immunic, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

September 29, 2021

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

September 21, 2021

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

August 5, 2021

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

July 18, 2021

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

July 14, 2021

Immunic, Inc. Announces Proposed Public Offering of Common Stock

July 13, 2021

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

July 11, 2021

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

June 30, 2021

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

May 31, 2021

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

May 5, 2021

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

April 14, 2021

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838

March 30, 2021

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

February 25, 2021

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

February 17, 2021

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

February 16, 2021

Immunic, Inc. to Participate in Investor Conferences in January

January 4, 2021

Immunic, Inc. to Participate in Investor Conferences in December

November 23, 2020

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

November 16, 2020

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

November 1, 2020

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

September 27, 2020

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

September 10, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

August 19, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 9, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

August 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

August 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

August 1, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

July 29, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

July 26, 2020

Immunic, Inc. to Join Russell 3000® Index

June 21, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

June 14, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

June 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

June 8, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

May 18, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

May 12, 2020

Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity

May 7, 2020

Immunic, Inc. Announces Pricing of $15 Million Financing

April 22, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

April 20, 2020

Immunic, Inc. Announces Changes to Executive Team

April 16, 2020

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

March 15, 2020

Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

January 7, 2020

Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips

November 18, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

October 14, 2019

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

October 9, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in October

September 29, 2019

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

September 17, 2019

Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019

September 10, 2019

Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

September 4, 2019

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis

August 11, 2019

Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity

August 7, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 68 decks. Every deck is listed under its year.